Hemostemix (CVE:HEM) Shares Down 17.1% – Time to Sell?

Hemostemix Inc. (CVE:HEMGet Free Report)’s share price was down 17.1% during mid-day trading on Thursday . The company traded as low as C$0.28 and last traded at C$0.32. Approximately 684,632 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 673,865 shares. The stock had previously closed at C$0.38.

Hemostemix Price Performance

The stock has a market cap of C$27.44 million, a price-to-earnings ratio of -15.75 and a beta of 0.20. The firm’s 50-day moving average is C$0.15 and its 200 day moving average is C$0.10.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Further Reading

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.